Sana Biotechnology (SANA) Goldman Sachs Cell Therapy Day summary

Industry outlook and advancements

• Allogeneic cell therapy is positioned as the next frontier, aiming for scalable, off-the-shelf solutions for hematologic malignancies, solid tumors, and autoimmune diseases.

• Overcoming immune rejection is central, with strategies like 'cloak' (immune evasion) and 'dagger' (countering alloreactive T-cells) being developed.

• Manufacturing science and facility investments are enabling production at a scale that could double current global CAR T patient capacity.

• Allogeneic therapies promise to simplify logistics, reduce costs, and increase accessibility compared to autologous approaches.

• The field is moving toward modular, gene-edited products that can be rapidly iterated and scaled.

Pipeline updates and clinical progress

• Cema-cel, an allogeneic CAR T, is in a pivotal frontline study for large B-cell lymphoma, with early data expected mid-2025 and a potential BLA filing in 2027.

• ALLO-316, targeting CD70 in renal cell carcinoma, showed a 30% response rate; updated data is expected by year-end.

• ALLO-329, a dual CD19/CD70 CAR for autoimmune diseases, uses CRISPR editing and aims to address both B- and T-cell components; IND submission is planned for Q1 2025.

• Sana's iPSC-derived beta cell program for type 1 diabetes is testing if gene-modified cells can survive and function without immunosuppression, with phase I data anticipated soon.

• Early phase I data for Sana's CD19 asset in autoimmune and B-cell malignancies show promising safety and B-cell depletion.

Strategic and technical challenges

• Lymphodepletion remains a key barrier; reducing or eliminating it is seen as critical for broader adoption, especially in autoimmune indications.

• Manufacturing and supply chain complexity require significant upfront capital, but once established, enable large-scale, cost-effective production.

• Site activation and patient recruitment are time-consuming but improving as awareness grows among rheumatologists and oncologists.

• Competitive differentiation will depend on durability, safety, and the ability to address both B- and T-cell pathology in autoimmune diseases.

• The field anticipates further advances in gene engineering to overcome resistance and expand into solid tumors.